Smith & Nephew consensus in focus, analysts keep a cautious hold on the shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 15:22.

Smith & Nephew (GB0009223206) stands in London trading with a clear analyst consensus picture. The stock is listed on the London Stock Exchange under the ticker SN and also trades as an ADR on the NYSE under SNN, giving it broad international visibility.

What analysts are signaling

Across the houses covered by MarketBeat, Smith & Nephew carries a consensus rating of Hold, with an average price target of about GBX 1,383 per share. This compares with a latest close around GBX 1,146 on London data as of June 25, 2026, implying roughly 20 percent upside to consensus fair value.

Eight analysts are listed with active recommendations, producing a rating score of 2.38 on a 0-to-4 scale, where higher values indicate a more positive stance. The shares currently trade on a trailing P/E ratio above 40 and a dividend yield of around 3.7 percent, a combination that helps explain the cautious tone versus faster-growing peers such as Stryker and Zimmer Biomet in the orthopedic and surgical devices segment.

Consensus targets and valuation

The documented price targets span a wide range, from as low as roughly GBX 13 at the bottom of the distribution to as high as GBX 2,760 at the top. Around the midpoint, the GBX 1,383 average target suggests that analysts see some room for recovery but are not uniformly confident enough to move to an outright Buy stance.

MarketBeat data show a market capitalization for Smith & Nephew of about GBP 12.6 billion at the latest close, placing the group as a mid- to large-cap name in European medtech. According to TradingKey, the New York–listed ADR SNN most recently closed at USD 30.23 on June 25, 2026, with very limited day-to-day volatility, pointing to a relatively stable risk profile in US trading hours.

The devices behind the stock

Smith & Nephew generates its revenue primarily from orthopedic reconstruction, sports medicine and advanced wound management systems. A representative product is its lineup of knee-replacement implants, which are used in surgical procedures worldwide alongside arthroscopic instruments and negative-pressure wound-therapy solutions for hospitals and specialist clinics.

Where the shares trade today

The Smith & Nephew shares (GB0009223206) most recently closed on the London Stock Exchange at GBX 1,146 on 2026-06-25, based on MarketBeat and exchange quote data. The ADRs under the ticker SNN settled at USD 30.23 on the NYSE on the same date.

This text is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. All data are based on sources cited in the article and may change over time.